Form 4: United Therapeutics EVP Sells Shares After Option Exercise

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 8,300 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp (UTHR), executed a series of transactions on January 15, 2026.
• These transactions involved the exercise of 8,300 stock options at an exercise price of $146.03 per share.
• Immediately following the option exercise, Mr. Mahon sold all 8,300 newly acquired shares of common stock.
• The sales were conducted in multiple trades at weighted average prices ranging from $468.324 to $474.74 per share.
• All transactions were executed pursuant to a pre-arranged Rule 10b5-1 plan established on August 11, 2025.
• After these transactions, Mr. Mahon beneficially owns 36,781 shares of common stock directly and 58,400 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (option exercise and sale) under a pre-arranged plan, which is common for executive compensation and diversification. It does not inherently signal positive or negative company performance or a change in fundamental outlook.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating a planned sale rather than an immediate reaction to new, non-public information.
• The sale prices for the common stock were significantly higher than the option exercise price, indicating a profitable transaction for the insider.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though the context of option exercise and diversification is common.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it is a report of an insider transaction.

Industry Context

This filing details a routine insider transaction, which is common for executives to manage their compensation and diversify personal holdings. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May observe an insider sale, but the context of a pre-arranged 10b5-1 plan mitigates concerns. The executive retains significant equity holdings in the company.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. Such transactions are common for executive compensation and personal financial planning and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. The executive retains significant equity holdings.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Share Sale, Executive Compensation, 10b5-1 Plan, Paul A. Mahon